Xu Li

Xu Li

Auto-generated profile, based on publicly available information

Xu Li

Department of Pathogenic Biology and Immunology, School of Basic Medical Science, Xiangnan University, Chenzhou 423000, Hunan, China

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 November 2023 in International Journal of Biological Macromolecules
Verified
Journal Article
Closed access
LYLifang Yuan
Lifang Yuan
XLXu Li
Xu Li
MLMinchao Li
Minchao Li
RBRongjun Bi
Rongjun Bi
YLYingrui Li
Yingrui Li
YSYuelong Shu
Yuelong Shu

19 February 2026 in Biology
Verified
Journal Article
Open access
PDF file
LYLifang Yuan
Lifang Yuan
ZOZhiyao Ouyang
Zhiyao Ouyang
YZYifan Zhao
Yifan Zhao
RBRongjun Bi
Rongjun Bi
YWYanjing Wu
Yanjing Wu
YCYongkun Chen
Yongkun Chen
Influenza’s pandemic threat is driven by antigenic drift, which limits the efficacy of conventional vaccines. To address this challenge, we established a clinical serum-anchored computational design pipeline for a broad-spectrum multi-epitope mRNA vaccine (MEMV), bridging the gap between pure in silico design and clinical applicability. Using 36 longitudinal sera (d0/d28/d365) from 12 well-characterized human cohorts (6 vaccine recipients and 6 influenza patients) and high-density antibody-peptide microarrays, we empirically identified 12 immunodominant B-cell linear epitopes from the nucleoprotein (NP) of influenza A (H1N1/H3N2) and B viruses. These experimentally validated epitopes were combined with in silico-predicted conserved helper T-lymphocyte (HTL)/cytotoxic T-lymphocyte (CTL) epitopes (from NP/HA/NA) to construct MEMVs candidates, ensuring high antigenicity, non-toxicity, and 95.63% global HLA coverage. Molecular docking and 100 ns molecular dynamics (MD) simulations confirmed favorable conformational compatibility between MEMVs and Toll-like receptor 3 (TLR3) in silico immunization via C-ImmSim predicted robust B/T-cell responses and protective cytokine (IFN-γ/IL-10) production. Collectively, this pipeline shortens the preliminary design cycle for influenza vaccines, provides a standard epitope-combination strategy, and offers direct targets for follow-up in vitro/in vivo experiments.